Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 19, 2020 - Issue 8
Submit an article Journal homepage
274
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics

Leanne J. Kossea Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, The NetherlandsCorrespondence[email protected]
View further author information
,
Gerda Weitsa Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, The NetherlandsView further author information
,
Harald E. Vonkemanb Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, The NetherlandsView further author information
,
Phyllis I. Spulsc Department of Dermatology, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health and Epidemiology, Immunity and Infections, The NetherlandsView further author information
,
Bart J.F. Van Den Bemtd Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands;e Department of Pharmacy, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Sander W. Tasf Department of Rheumatology & Clinical Immunology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam, The NetherlandsView further author information
,
Frank Hoentjeng Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Mike T. Nurmohamedh Department Rheumatology, Reade & Amsterdam Rheumatology & Immunology Center (ARC), The NetherlandsView further author information
,
Martijn B.A. Van Doorni Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The NetherlandsView further author information
,
Eugène P. Van Puijenbroeka Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, The Netherlands;j Department of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The NetherlandsView further author information
&
Naomi T. Jessuruna Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, The NetherlandsView further author information
 show all
Pages 1049-1054 | Received 30 Jan 2020, Accepted 08 Jun 2020, Published online: 07 Jul 2020

References

  • Strand V, Mysler E, Moots RJ, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5(2):e001040. [01-12-2019];[10].
  • Bartlett SJ, De Leon E, Orbai A-M, et al. Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. Rheumatol. 2019. [01-12-2019];[9]. 10.1093/rheumatology/kez506.
  • Oosterhuis I, van Hunsel FPAM, van Puijenbroek EP. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands. Drug Saf. 2012;35(3):221–232.
  • Rolfes L, van Hunsel F, van Grootheest K, et al., Feedback for patients reporting adverse drug reactions; satisfaction and expectations. Expert Opin Drug Saf. 14(5): 625–632. 2015. .
  • Cornelissen L, van Puijenbroek E, van Grootheest K. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):76–81.
  • Kosse LJ, Jessurun NT, Hebing RCF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatol. 2019. [01-11-2019];[9]. 10.1093/rheumatology/kez412.
  • Harpe SE. How to analyze Likert and other rating scale data. Curr Pharm Teach Learn. 2015;7(6):836–850.
  • Gutknecht M, Schaarschmidt ML, Herrlein O, et al., A systematic review on methods used to evaluate patient preferences in psoriasis treatments. J Eur Acad Dermatol Venereol. 30(9): 1454–1464. 2016. .
  • Ho M, Saha A, McCleary KK, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746–750. .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.